pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
Updated: Feb 15, 2022
Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada.
This submission was led by patient advocates from Lung Cancer Canada and Ontario Lung Association, and supported by physicians. Thanks to the many ROS1ders who shared their stories with Lung Cancer Canada—you helped make a difference.
From the pCODR recommendation:
“The patient input included 259 patients who were ROS1 positive and caregivers from 32 countries who supported the use of crizotinib. Overall, from the perspectives of patients with ROS1-positive NSCLC, they value a chance to extend their life and spend more time with their families by having a treatment that is effective, and improves their symptoms and outcomes.”